Subscribe To
Amber ophthalmics announces positive topline phase 2 data evaluating nexagon® for the treatment of persistent corneal epithelial defect (pced)
••Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone••NEXAGON was well-...
January 9, 2023, 12:31 pm
: kala pharmaceuticals stock up 750% in 3 days after upbeat fda news on pced treatment
Shares of Kala Pharmaceuticals Inc. KALA have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceuti...
December 30, 2022, 5:02 pm
Kala pharmaceuticals stock up 750% in 3 days after upbeat fda news on pced treatment
Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the bioph...
December 30, 2022, 12:02 pm
: kala pharmaceuticals stock rockets nearly 300% after fda oks ind application for pced treatment
Shares of Kala Pharmaceuticals Inc. KALA quadrupled in very volatile trading Wednesday, after the biopharmaceutical company said the Food and Drug Adm...
December 28, 2022, 5:44 pm
Kala pharmaceuticals stock rockets after fda accepts ind application for pced treatment
Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and D...
December 28, 2022, 6:48 am
Kala pharmaceuticals announces fda acceptance of ind application for kpi-012 for the treatment of pced
— On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 — — Received remaining $25 million investment under previousl...
December 27, 2022, 9:01 pm